Combretastatin A-1 phosphate (OXi-4503) tetrasodium, a prodrug of Combretastatin A-1, is a tubulin-binding microtubule polymerization inhibitor that targets the colchicine-binding site. By inducing tubulin depolymerization, Combretastatin A-1 phosphate tetrasodium inhibits the Wnt β-catenin pathway and leads to the deactivation of AKT. It possesses both anti-tumor and anti-vascular properties.
EG01377 has antiangiogenic, antimigratory, and antitumor effects.EG01377 is a neuropilin-1 (NRP1) antagonist, with a Kd of 1.32 μM for NRP1-b1, and IC50s of both 609 nM for NRP1-a1 and NRP1-b1, but shows no effect on NRP2.
Enniatin A1 possesses anticarcinogenic properties by induction of apoptosis and disruption of ERK signalling pathway. Enniatin A1 inhibits ACAT with an IC50 of 49 μM in rat liver microsomes. Enniatin A1 isolated from Fusarium mycotoxins is a cyclic hexadepsipeptide consisting of alternating D-α-hydroxyisovaleric acids and N-methyl-L-amino acids.